New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
08:50 EDTRPRXRepros Therapeutics weakness creates buying opportunity, says Roth Capital
After Repros' stock sold off yesterday, Roth Capital spoke with the company's management and is more confident that the outlook for the company's Androxal drug remains positive. The firm maintains a $19 price target and Buy rating on the stock.
News For RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
14:18 EDTRPRXRepros Therapeutics April volatility elevated at 144
Repros Therapeutics April call option implied volatility is at 144, May is at 108, August is at 107; compared to its 26-week average of 103 according to Track Data, suggesting large near term price movement
March 16, 2015
14:54 EDTRPRXFDA accepting Androxal NDA can be catalyst for Repros, says Brean Capital
Subscribe for More Information
09:28 EDTRPRXRepros Therapeutics reports Q4 EPS (31c), consensus (34c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use